<DOC>
	<DOCNO>NCT00247663</DOCNO>
	<brief_summary>- To investigate safety letrozole monotherapy dose 1.0 mg/day fadrozole monotherapy dose 2.0mg Japanese postmenopausal patient advance breast cancer participate double blind study .</brief_summary>
	<brief_title>Extension Study 1.0mg Dose Letrozole Therapy Postmenopausal Patients With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Patients participate double blind study Patients intolerable toxicity . Patients confirm progressive disease double blind study . Patients receive concurrent anticancer therapy double blind study .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Aromatase inhibitor</keyword>
	<keyword>letrozole</keyword>
	<keyword>breast cancer</keyword>
</DOC>